Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

Journal of Molecular Diagnostics

Volumn 19, Issue 2, 2017, Pages 187-225

  Sepulveda, Antonia R ^a   Hamilton, Stanley R ^b   Allegra, Carmen J ^c   Grody, Wayne ^d   Cushman Vokoun, Allison M ^e   Funkhouser, William K ^f   Kopetz, Scott E ^b   Lieu, Christopher ^g   Lindor, Noralane M ^h   Minsky, Bruce D ^b   Monzon, Federico A ⁱ   Sargent, Daniel J ^j   Singh, Veena M ^k   Willis, Joseph ^l   Clark, Jennifer ^m   Colasacco, Carol ⁿ   Rumble, R Bryan ^o   Temple Smolkin, Robyn ^p   Ventura, Christina B ⁿ   Nowak, Jan A ^q  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ Castle Biosciences   (United States)

^j MAYO CLINIC   (United States)

^k Biocept   (United States)

^l CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m American Society for Clinical Pathology   (United States)

ⁿ Molecular Pathology Division   (United States)

^o AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^p Association for Molecular Pathology   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; CLINICAL PRACTICE; COLORECTAL CANCER; GENE MUTATION; HUMAN; LABORATORY TEST; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; ONCOLOGY; PRACTICE GUIDELINE; REVIEW; SIGNAL TRANSDUCTION; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; GENE FREQUENCY; GENETICS; GENOMIC INSTABILITY; META ANALYSIS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; MUTATION RATE; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; GENE FREQUENCY; GENOMIC INSTABILITY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUTATION; MUTATION RATE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85011586132     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2016.11.001     Document Type: Review

References (152)

1. 1 Febbo, P.G., Ladanyi, M., Aldape, K.D., et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw 9 Suppl 5 (2011), S1–S33.
2. 2 Grothey, A., EGFR antibodies in colorectal cancer: where do they belong?. J Clin Oncol 28 (2010), 4668–4670, 10.1200/JCO.2010.29.3407.
3. 3 De Roock, W., Claes, B., Bernasconi, D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11 (2010), 753–762, 10.1016/S1470-2045(10)70130-3.
4. 4 De Roock, W., De Vriendt, V., Normanno, N., et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12 (2011), 594–603, 10.1016/S1470-2045(10)70209-6.
5. 5 Rubenstein, J.H., Enns, R., Heidelbaugh, J., et al. American Gastroenterological Association Institute guideline on the diagnosis and management of Lynch syndrome. Gastroenterology 149 (2015), 777–782, 10.1053/j.gastro.2015.07.036.
6. 6 Des Guetz, G., Schischmanoff, O., Nicolas, P., et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? a systematic review with meta-analysis. Eur J Cancer 45 (2009), 1890–1896, 10.1016/j.ejca.2009.04.018.
7. 7 Guastadisegni, C., Colafranceschi, M., Ottini, L., et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46 (2010), 2788–2798, 10.1016/j.ejca.2010.05.009.
8. 8 Gavin, P.G., Colangelo, L.H., Fumagalli, D., et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18 (2012), 6531–6541, 10.1158/1078-0432.CCR-12-0605.
9. 9 Institute of Medicine, Clinical Practice Guidelines We Can Trust. 2011, National Academies Press, Washington, DC.
10. 10 National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinicl practice guidelines. 1999. Available at https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp.30.pdf. Accessed March 23, 2016.
11. 11 Guyatt, G.H., Oxman, A.D., Vist, G.E., GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926, 10.1136/bmj.39489.470347.AD.
12. 12 Sorich, M.J., Wiese, M.D., Rowland, A., et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26 (2015), 13–21, 10.1093/annonc/mdu378.
13. 13 Ibrahim, E.M., Abouelkhair, K.M., Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials. Med Oncol 28 Suppl 1 (2011), S310–S317, 10.1007/s12032-010-9760-4.
14. 14 Modest, D.P., Brodowicz, T., Stintzing, S., et al. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology 83 (2012), 241–247, 10.1159/000339534.
15. 15 Petrelli, F., Borgonovo, K., Cabiddu, M., et al. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 26 (2011), 823–833, 10.1007/s00384-011-1149-0.
16. 16 Zhou, S.W., Huang, Y.Y., Wei, Y., et al. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PLoS One, 7, 2012, e50925, 10.1371/journal.pone.0050925.
17. 17 Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765, 10.1056/NEJMoa0804385.
18. 18 Adelstein, B.A., Dobbins, T.A., Harris, C.A., et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 47 (2011), 1343–1354, 10.1016/j.ejca.2011.03.031.
19. 19 Allegra, C.J., Jessup, J.M., Somerfield, M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009), 2091–2096, 10.1200/JCO.2009.21.9170.
20. 20 Baas, J.M., Krens, L.L., Guchelaar, H.J., et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 16 (2011), 1239–1249, 10.1634/theoncologist.2011-0024.
21. 21 Chen, J., Ye, Y., Sun, H., et al. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 71 (2013), 265–272, 10.1007/s00280-012-2005-9.
22. 22 Dahabreh, I.J., Terasawa, T., Castaldi, P.J., et al. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 154 (2011), 37–49, 10.7326/0003-4819-154-1-201101040-00006.
23. 23 De Roock, W., Jonker, D.J., Di Nicolantonio, F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304 (2010), 1812–1820, 10.1001/jama.2010.1535.
24. 24 Health Quality Ontario, KRAS testing for Anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser 10 (2010), 1–49.
25. 25 Hoyle, M., Crathorne, L., Peters, J., et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 17 (2013), 1–237.
26. 26 Ibrahim, E.M., Zekri, J.M., Bin Sadiq, B.M., Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis 25 (2010), 713–721, 10.1007/s00384-010-0927-4.
27. 27 Jiang, Z., Li, C., Li, F., et al. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One, 8, 2013, e56205, 10.1371/journal.pone.0056205.
28. 28 Ku, G.Y., Haaland, B.A., de Lima Lopes, G. Jr., Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 70 (2012), 231–238, 10.1007/s00280-012-1898-7.
29. 29 Lin, A.Y., Buckley, N.S., Lu, A.T., et al. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer 10 (2011), 63–69, 10.3816/CCC.2011.n.009.
30. 30 Linardou, H., Dahabreh, I.J., Kanaloupiti, D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008), 962–972, 10.1016/S1470-2045(08)70206-7.
31. 31 Loupakis, F., Cremolini, C., Salvatore, L., et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 118 (2012), 1523–1532, 10.1002/cncr.26460.
32. 32 Mao, C., Huang, Y.F., Yang, Z.Y., et al. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 119 (2013), 714–721, 10.1002/cncr.27804.
33. 33 Mao, C., Yang, Z.Y., Hu, X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23 (2012), 1518–1525, 10.1093/annonc/mdr464.
34. 34 Petrelli, F., Barni, S., Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 27 (2012), 997–1004, 10.1007/s00384-012-1438-2.
35. 35 Petrelli, F., Coinu, A., Cabiddu, M., et al. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol, 30, 2013, 650, 10.1007/s12032-013-0650-4.
36. 36 Qiu, L.X., Mao, C., Zhang, J., et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 46 (2010), 2781–2787, 10.1016/j.ejca.2010.05.022.
37. 37 Ren, J., Li, G., Ge, J., et al. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 55 (2012), 913–923, 10.1097/DCR.0b013e318251d8d9.
38. 38 Tsoukalas, N., Tzovaras, A.A., Tolia, M., et al. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. J BUON 17 (2012), 73–78.
39. 39 Vale, C.L., Tierney, J.F., Fisher, D., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 38 (2012), 618–625, 10.1016/j.ctrv.2011.11.002.
40. 40 Yang, Z.Y., Shen, W.X., Hu, X.F., et al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. J Hematol Oncol, 5, 2012, 52, 10.1186/1756-8722-5-52.
41. 41 Zhang, L., Ma, L., Zhou, Q., Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. Int J Colorectal Dis 26 (2011), 1025–1033, 10.1007/s00384-011-1197-5.
42. 42 Ross, J.S., Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Arch Pathol Lab Med 136 (2012), 1298–1307, 10.5858/arpa.2011-0478-RA.
43. 43 Bando, H., Yoshino, T., Shinozaki, E., et al. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer, 13, 2013, 405, 10.1186/1471-2407-13-405.
44. 44 Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034, 10.1056/NEJMoa1305275.
45. 45 Etienne-Grimaldi, M.C., Mahamat, A., Chazal, M., et al. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Br J Cancer 110 (2014), 2728–2737, 10.1038/bjc.2014.213.
46. 46 Van Cutsem, E., Lenz, H.J., Kohne, C.H., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33 (2015), 692–700, 10.1200/JCO.2014.59.4812.
47. 47 Xu, Q., Xu, A.T., Zhu, M.M., et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 14 (2013), 409–416, 10.1111/1751-2980.12063.
48. 48 Yuan, Z.X., Wang, X.Y., Qin, Q.Y., et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One, 8, 2013, e65995, 10.1371/journal.pone.0065995.
49. 49 Forbes, S.A., Bhamra, G., Bamford, S., et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet, 2008 chap 10:unit 10.11.
50. 50 Lin, J.S., Webber, E.M., Senger, C.A., et al. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1 (2011), 650–662.
51. 51 Mao, C., Liao, R.Y., Qiu, L.X., et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 38 (2011), 2219–2223, 10.1007/s11033-010-0351-4.
52. 52 Parsons, M.T., Buchanan, D.D., Thompson, B., et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49 (2012), 151–157, 10.1136/jmedgenet-2011-100714.
53. 53 Cui, D., Cao, D., Yang, Y., et al. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep 41 (2014), 1291–1298, 10.1007/s11033-013-2974-8.
54. 54 Lochhead, P., Kuchiba, A., Imamura, Y., et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105 (2013), 1151–1156, 10.1093/jnci/djt173.
55. 55 Rowland, A., Dias, M.M., Wiese, M.D., et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112 (2015), 1888–1894, 10.1038/bjc.2015.173.
56. 56 Cremolini, C., Loupakis, F., Antoniotti, C., et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16 (2015), 1306–1315, 10.1016/S1470-2045(15)00122-9.
57. 57 Corcoran, R.B., Atreya, C.E., Falchook, G.S., et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis [ASCO meeting abstract 3517]. J Clin Oncol, 2014 32:5s. http://meetinglibrary.asco.org/content/131743-144. Accessed November 18, 2016.
58. 58 Bendell, J.C., Atreya, C.E., André, T., et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T) BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC) [ASCO meeting abstract 3515]. J Clin Oncol, 2014 32:5s. http://meetinglibrary.asco.org/content/131642-144. Accessed November 18, 2016.
59. 59 Temraz, S., Mukherji, D., Shamseddine, A., Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers. Int J Mol Sci 16 (2015), 22976–22988, 10.3390/ijms160922976.
60. 60 Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial [published online January 14, 2016]. JAMA Oncol doi: 10.1001/jamaoncol.2015.5225.
61. 61 Barras, D., BRAF mutation in colorectal cancer: an update. Biomark Cancer 7 (2015), 9–12, 10.4137/BIC.S25248.
62. 62 Geiersbach, K.B., Samowitz, W.S., Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135 (2011), 1269–1277, 10.5858/arpa.2011-0035-RA.
63. 63 Barrow, E., Hill, J., Evans, D.G., Cancer risk in lynch syndrome. Fam Cancer 12 (2013), 229–240, 10.1007/s10689-013-9615-1.
64. 64 Schmeler, K.M., Lynch, H.T., Chen, L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006), 261–269, 10.1056/NEJMoa052627.
65. 65 Vasen, H.F., Blanco, I., Aktan-Collan, K., et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62 (2013), 812–823, 10.1136/gutjnl-2012-304356.
66. 66 Funkhouser, W.K. Jr., Lubin, I.M., Monzon, F.A., et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the Association for Molecular Pathology. J Mol Diagn 14 (2012), 91–103, 10.1016/j.jmoldx.2011.11.001.
67. 67 Kawakami, H., Zaanan, A., Sinicrope, F.A., Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol 6 (2015), 676–684.
68. 68 Diaz, L.A. Jr., Le, D.T., PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med, 373, 2015, 1979, 10.1056/NEJMc1510353.
69. 69 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520, 10.1056/NEJMoa1500596.
70. 70 Le, D.T., Uram, J.N., Wang, H., et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer [ASCO meeting abstract 103]. J Clin Oncol, 2016 34. http://meetinglibrary.asco.org/content/167415-176. Accessed November 18, 2016.
71. 71 Yang, Z.Y., Wu, X.Y., Huang, Y.F., et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 133 (2013), 1914–1925, 10.1002/ijc.28153.
72. 72 Pietrantonio, F., Petrelli, F., Coinu, A., et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51 (2015), 587–594, 10.1016/j.ejca.2015.01.054.
73. 73 Wu, S., Gan, Y., Wang, X., et al. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. J Cancer Res Clin Oncol 139 (2013), 891–900, 10.1007/s00432-013-1400-x.
74. 74 Karapetis, C.S., Jonker, D., Daneshmand, M., et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res 20 (2014), 744–753, 10.1158/1078-0432.CCR-13-0606.
75. 75 Liao, X., Morikawa, T., Lochhead, P., et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 18 (2012), 2257–2268, 10.1158/1078-0432.CCR-11-2410.
76. 76 Ogino, S., Liao, X., Imamura, Y., et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105 (2013), 1789–1798, 10.1093/jnci/djt298.
77. 77 Ogino, S., Nosho, K., Kirkner, G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27 (2009), 1477–1484, 10.1200/JCO.2008.18.6544.
78. 78 Flossmann, E., Rothwell, P.M., Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 (2007), 1603–1613, 10.1016/S0140-6736(07)60747-8.
79. 79 Jacobs, E.J., Thun, M.J., Bain, E.B., et al., A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99 (2007), 608–615, 10.1093/jnci/djk132.
80. 80 Chan, A.T., Giovannucci, E.L., Meyerhardt, J.A., et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134 (2008), 21–28, 10.1053/j.gastro.2007.09.035.
81. 81 Domingo, E., Church, D.N., Sieber, O., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31 (2013), 4297–4305, 10.1200/JCO.2013.50.0322.
82. 82 Liao, X., Lochhead, P., Nishihara, R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367 (2012), 1596–1606, 10.1056/NEJMoa1207756.
83. 83 Kothari, N., Kim, R., Jorissen, R.N., et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol 54 (2015), 487–492, 10.3109/0284186X.2014.990158.
84. 84 Berg, M., Danielsen, S.A., Ahlquist, T., et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One, 5, 2010, e13978, 10.1371/journal.pone.0013978.
85. 85 Shen, Y., Yang, J., Xu, Z., et al. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. World J Gastroenterol 18 (2012), 2712–2718, 10.3748/wjg.v18.i21.2712.
86. 86 Wang, Z.H., Gao, Q.Y., Fang, J.Y., Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemother Pharmacol 69 (2012), 1647–1655, 10.1007/s00280-012-1886-y.
87. 87 Nassif, N.T., Lobo, G.P., Wu, X., et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23 (2004), 617–628, 10.1038/sj.onc.1207059.
88. 88 Sawai, H., Yasuda, A., Ochi, N., et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol, 8, 2008, 56, 10.1186/1471-230X-8-56.
89. 89 Lin, M.S., Huang, J.X., Chen, W.C., et al. Expression of PPARgamma and PTEN in human colorectal cancer: an immunohistochemical study using tissue microarray methodology. Oncol Lett 2 (2011), 1219–1224.
90. 90 Li, X.H., Zheng, H.C., Takahashi, H., et al. PTEN expression and mutation in colorectal carcinomas. Oncol Rep 22 (2009), 757–764.
91. 91 Colakoglu, T., Yildirim, S., Kayaselcuk, F., et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?. Am J Surg 195 (2008), 719–725, 10.1016/j.amjsurg.2007.05.061.
92. 92 Eklof, V., Wikberg, M.L., Edin, S., et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108 (2013), 2153–2163, 10.1038/bjc.2013.212.
93. 93 Price, T.J., Hardingham, J.E., Lee, C.K., et al. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Med 2 (2013), 277–285, 10.1002/cam4.75.
94. 94 Frattini, M., Saletti, P., Romagnani, E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97 (2007), 1139–1145, 10.1038/sj.bjc.6604009.
95. 95 Perrone, F., Lampis, A., Orsenigo, M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20 (2009), 84–90, 10.1093/annonc/mdn541.
96. 96 Sartore-Bianchi, A., Martini, M., Molinari, F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69 (2009), 1851–1857, 10.1158/0008-5472.CAN-08-2466.
97. 97 Negri, F.V., Bozzetti, C., Lagrasta, C.A., et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102 (2010), 162–164, 10.1038/sj.bjc.6605471.
98. 98 Laurent-Puig, P., Cayre, A., Manceau, G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27 (2009), 5924–5930, 10.1200/JCO.2008.21.6796.
99. 99 Tol, J., Dijkstra, J.R., Klomp, M., et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46 (2010), 1997–2009, 10.1016/j.ejca.2010.03.036.
100. 100 Ulivi, P., Capelli, L., Valgiusti, M., et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med, 10, 2012, 87, 10.1186/1479-5876-10-87.
101. 101 Cejas, P., Lopez-Gomez, M., Aguayo, C., et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. Curr Cancer Drug Targets 12 (2012), 124–131, 10.2174/156800912799095162.
102. 102 Vakiani, E., Janakiraman, M., Shen, R., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30 (2012), 2956–2962, 10.1200/JCO.2011.38.2994.
103. 103 Lee, K.H., Kim, J.S., Lee, C.S., et al. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. J Surg Oncol 111 (2015), 1059–1064, 10.1002/jso.23936.
104. 104 Aisner, D.L., Deshpande, C., Baloch, Z., et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 41 (2013), 316–323, 10.1002/dc.21851.
105. 105 Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137 (2013), 828–860, 10.5858/arpa.2012-0720-OA.
106. 106 Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014, 224ra224.
107. 107 Clinical Laboratory Improvement Amendments of 1988. 42 CFR §493.1351–1495 (1992).
108. 108 Sakai, K., Tsurutani, J., Yamanaka, T., et al. Extended RAS and BRAF mutation analysis using next-generation sequencing. PLoS One, 10, 2015, e0121891, 10.1371/journal.pone.0121891.
109. 109 Salto-Tellez, M., Gonzalez de Castro, D., Next-generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol 234 (2014), 5–10, 10.1002/path.4365.
110. 110 Cottrell, C.E., Al-Kateb, H., Bredemeyer, A.J., et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn 16 (2014), 89–105, 10.1016/j.jmoldx.2013.10.002.
111. 111 Clinical Laboratory Improvement Amendments of 1988. 42 CFR §493.1253 (2003).
112. 112 College of American Pathologists. CAP laboratory accreditation checklists. Available at http://www.cap.org/apps/cap.portal. Accessed November 18, 2016.
113. 113 Clinical and Laboratory Standards Institute. Establishing Molecular Testing in Clinical Laboratory Environments, Approved Guideline (MM19-A). Wayne, PA: Clinical Laboratory Standards Institute; 2011.
114. 114 Halling, K.C., Schrijver, I., Persons, D.L., Test verification and validation for molecular diagnostic assays. Arch Pathol Lab Med 136 (2012), 11–13, 10.5858/arpa.2011-0212-ED.
115. 115 Clinical and Laboratory Standards Institute. Molecular Diagnostic Methods for Solid Tumors (Nonhematological Neoplasms) (MM23-ED 1). Wayne, PA: Clinical Laboratory Standards Institute; 2015.
116. 116 Ogino, S., Gulley, M.L., den Dunnen, J.T., et al. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 9 (2007), 1–6, 10.2353/jmoldx.2007.060081.
117. 117 Fishel, R., Lescoe, M.K., Rao, M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (1993), 1027–1038.
118. 118 Bronner, C.E., Baker, S.M., Morrison, P.T., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368 (1994), 258–261, 10.1038/368258a0.
119. 119 Liu, B., Nicolaides, N.C., Markowitz, S., et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9 (1995), 48–55, 10.1038/ng0195-48.
120. 120 Gologan, A., Sepulveda, A.R., Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin Lab Med 25 (2005), 179–196, 10.1016/j.cll.2004.12.001.
121. 121 Fitzgibbons, P.L., Bradley, L.A., Fatheree, L.A., et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 138 (2014), 1432–1443, 10.5858/arpa.2013-0610-CP.
122. 122 Sepulveda, A.R., The importance of microsatellite instability in colonic neoplasms. Medscape, 2008, 571610 www.medscape.org/viewarticle/571610. Accessed November 18, 2016.
123. 123 Hatch, S.B., Lightfoot, H.M. Jr., Garwacki, C.P., et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res 11 (2005), 2180–2187, 10.1158/1078-0432.CCR-04-0234.
124. 124 Watson, N., Grieu, F., Morris, M., et al. Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 9 (2007), 472–478, 10.2353/jmoldx.2007.060162.
125. 125 Cicek, M.S., Lindor, N.M., Gallinger, S., et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 13 (2011), 271–281, 10.1016/j.jmoldx.2010.12.004.
126. 126 Wong, N.A., Gonzalez, D., Salto-Tellez, M., et al. RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol 67 (2014), 751–757, 10.1136/jclinpath-2014-202467.
127. 127 Biagi, J.J., Raphael, M.J., Mackillop, W.J., et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305 (2011), 2335–2342, 10.1001/jama.2011.749.
128. 128 Franklin, W.A., Haney, J., Sugita, M., et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 12 (2010), 43–50, 10.2353/jmoldx.2010.080131.
129. 129 Laosinchai-Wolf, W., Ye, F., Tran, V., et al. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. J Clin Pathol 64 (2011), 30–36, 10.1136/jcp.2010.081539.
130. 130 Ma, E.S., Wong, C.L., Law, F.B., et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 62 (2009), 886–891, 10.1136/jcp.2008.063677.
131. 131 Pinto, P., Rocha, P., Veiga, I., et al. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 204 (2011), 439–446, 10.1016/j.cancergen.2011.07.003.
132. 132 Tol, J., Dijkstra, J.R., Vink-Borger, M.E., et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 14 (2010), 2122–2131, 10.1111/j.1582-4934.2009.00788.x.
133. 133 Buxhofer-Ausch, V., Ausch, C., Zeillinger, R., et al. Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens. Dis Markers 34 (2013), 171–177, 10.1155/2013/740659.
134. 134 Carotenuto, P., Roma, C., Rachiglio, A.M., et al. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11 (2010), 1169–1179, 10.2217/pgs.10.86.
135. 135 Cavallini, A., Valentini, A.M., Lippolis, C., et al. KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res 30 (2010), 5251–5256.
136. 136 Chang, Y.S., Yeh, K.T., Hsu, N.C., et al. Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. Clin Biochem 43 (2010), 296–301, 10.1016/j.clinbiochem.2009.10.007.
137. 137 Chen, Y.L., Chang, Y.S., Chang, J.G., et al. Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis. J Chromatogr A 1216 (2009), 5147–5154, 10.1016/j.chroma.2009.04.083.
138. 138 Chow, L., Lin, P.C., Chang, J.S., et al. Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ Mol Mutagen 53 (2012), 22–31, 10.1002/em.20673.
139. 139 Kristensen, L.S., Daugaard, I.L., Christensen, M., et al. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Hum Mutat 31 (2010), 1366–1373, 10.1002/humu.21358.
140. 140 Kristensen, L.S., Kjeldsen, T.E., Hager, H., et al. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. BMC Cancer, 12, 2012, 548, 10.1186/1471-2407-12-548.
141. 141 Lang, A.H., Drexel, H., Geller-Rhomberg, S., et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAFJ. Mol Diagn 13 (2011), 23–28, 10.1016/j.jmoldx.2010.11.007.
142. 142 Sundstrom, M., Edlund, K., Lindell, M., et al. KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer, 10, 2010, 660, 10.1186/1471-2407-10-660.
143. 143 Viray, H., Li, K., Long, T.A., et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med 137 (2013), 1545–1549, 10.5858/arpa.2012-0561-CP.
144. 144 Nardon, E., Glavac, D., Benhattar, J., et al. A multicenter study to validate the reproducibility of MSI testing with a panel of 5 quasimonomorphic mononucleotide repeats. Diagn Mol Pathol 19 (2010), 236–242, 10.1097/PDM.0b013e3181db67af.
145. 145 Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003), 247–257, 10.1056/NEJMoa022289.
146. 146 Jover, R., Zapater, P., Castells, A., et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45 (2009), 365–373, 10.1016/j.ejca.2008.07.016.
147. 147 Human Genome Variation Society. Human Genome Variation Society website. www.hgvs.org. Updated September 25, 2016. Accessed November 18, 2016.
148. 148 Richards, S., Aziz, N., Bale, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (2015), 405–424, 10.1038/gim.2015.30.
149. 149 Sukhai, M.A., Craddock, K.J., Thomas, M., et al. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med 18 (2016), 128–136, 10.1038/gim.2015.47.
150. 150 Kalman, L.V., Lubin, I.M., Barker, S., et al. Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics. Arch Pathol Lab Med 137 (2013), 983–988, 10.5858/arpa.2012-0311-RA.
151. 151 Schrijver, I., Aziz, N., Jennings, L.J., et al. Methods-based proficiency testing in molecular genetic pathology. J Mol Diagn 16 (2014), 283–287, 10.1016/j.jmoldx.2014.02.002.
152. 152 Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586, 10.1200/JCO.2012.45.2011.